TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03294083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexastimogene Devacirepvec (Pexa-Vec)
Description: Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexastimogene Devacirepvec (Pexa-Vec)
Description: Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexastimogene Devacirepvec (Pexa-Vec)
Description: Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexastimogene Devacirepvec (Pexa-Vec)
Description: Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexastimogene Devacirepvec (Pexa-Vec)
Description: Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
Study: NCT04014998

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality
Description: Virtual reality group will have virtual reality for 20 minutes in addition to motor control exercises for 20 minutes. Virtual reality will apply using Oculus Go. On the other hand control group will have only exercise for 40 minutes. Exercises will include same exercises in both groups, but exercise group will perform exercises twice compared to virtual reality group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality group will have virtual reality for 20 minutes in addition to motor control exercises for 20 minutes. Virtual reality will apply using Oculus Go. On the other hand control group will have only exercise for 40 minutes. Exercises will include same exercises in both groups, but exercise group will perform exercises twice compared to virtual reality group.
Study: NCT03746678

Intervention type: OTHER
Intervention: C-Care Mobile Application
Description: C-care is a mobile application developed based on previous research at the IWK Health Centre. It contains topics relevant to Cesarean delivery and the recovery process, which the patient could access at anytime. Patient engagement with the application will be monitored anonymously for 30 days after delivery. On days one to five after delivery, patients will receive a short self-monitoring questionnaire (approximately 1 minute). At the end of two weeks (14 days), patients will complete an online survey regarding overall satisfaction, potential impact on care, usability and feasibility problems. At any point during the study, patients can email us to report any problems with the application.
Study: NCT03267030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Administration of 1-7 doses of 150 IU/kg IV infusion. (every 2 weeks for a maximum of 4 doses and every 6 weeks for maximum 3 doses).
Study: NCT05008237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel plus Cisplatin
Description: D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks Treatment will be continued until disease progression or unacceptable toxic effects.
Study: NCT02982382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulative Therapy
Description: Subjects will receive techniques of High Velocity and Low Amplitude (HVLA) or grade V manipulation to the lumbar region (lumbar roll), and pain education based on the biopsychosocial approach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Education
Description: Individuals will receive pain education based in a biopsychosocial approach

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pain Education
Description: Individuals will receive pain education based in a biopsychosocial approach

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The individuals will receive a simulation of spinal manipulation (sham) involving manual contact over lumbar region totaling 5 minutes.
Study: NCT04195997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Patients would be given anticoagulant therapy with bivalirudin in left atrial appendage occusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: heparin during left atrial appendage occlusion.
Study: NCT02950753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer Solution
Description: Fluid bolus of Lactated Ringer solution (30ml/kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Fluid bolus or Normal Saline (30ml/kg).
Study: NCT02917447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESTRESS-WV
Description: This is an online intervention for PTSD tailored for women Veterans. The intervention is based on cognitive behavioral therapy (CBT). The goal of CBT is to help people recognize and address their thoughts and behaviors in positive ways with the aim of improving their ability to function as well as possible in their lives. Participants will be asked to log on to the website twice per week for about 30-60 minutes each time. Homework assignments will include stress management skills that participants will be asked to practice and apply. A study coach will call each participant once a week for 8 weeks for about 15 minutes to review their progress with the program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Phone Monitoring
Description: A study coach will call participants once a week for 8 weeks for approximately 15 minutes. The coach will assess participants' PTSD symptoms and safety. She will encourage participants to use the time on the call to discuss any current life issues or problems that they would like. Active listening and rephrasing will be used, while teaching cognitive-behavioral strategies will be avoided.
Study: NCT04383002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: iNO will be given at 160ppm for 6 hours, once a day, for 2 days
Study: NCT02663089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK961081 solution for IV infusion
Description: Subjects will receive 10 mL of solution equivalent to 4 mcg of \[14C\]-GSK961081 (approximately 6.2 kilobecquerel \[kBq\]) intravenously as a single dose over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK961081 oral solution
Description: Subjects will receive 10 mL of solution equivalent to 200 mcg of \[14C\]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 dry powder for inhalation
Description: Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.
Study: NCT04648293

Intervention type: DEVICE
Intervention: Starling
Description: Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance that measures the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood. Baxter Healthcare's Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode. Four electrodes are placed at specific areas of the thorax, the impedance to the current flow calculated, and the electrical bioreactance waveform constructed. This information is used to determine cardiac output, and measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling device.

Intervention type: DEVICE
Intervention: Starling
Description: Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance that measures the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood. Baxter Healthcare's Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode. Four electrodes are placed at specific areas of the thorax, the impedance to the current flow calculated, and the electrical bioreactance waveform constructed. This information is used to determine cardiac output, and measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling device.
Study: NCT02140684

Intervention type: DEVICE
Intervention: eNO monitoring
Description: Patient undergoing review with eNO monitored using either NIOX MINO® and NIOX Flex®
Study: NCT02588625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04452799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hesperidin and Diosmin mixture
Description: Interventional Clinical Trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin and Diosmin mixture
Description: Interventional Clinical Trial
Study: NCT03536676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Egg-cellent' Breakfast in the Classroom
Description: Includes the additional 2 eggs per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast in the Classroom
Description: Receives the standard meal for Breakfast in the Classroom
Study: NCT00231296

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac CryoCor Cryoablation System
Description: Treatment with CryoCor Cardiac Cryoablation system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Description: Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
Study: NCT02338323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzbromarone
Description: It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
Study: NCT03025529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation or TMS is a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. This magnetic field can pass through the head safely and painlessly. TMS can be used to change activity in the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham Transcranial Magnetic Stimulation or sham TMS is like active TMS, a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. TMS can be used to change activity in the brain but in this intervention, the coil will be angled 90 degrees from the scalp, resting on one wing of the coil, and therefore will not be delivering active TMS.
Study: NCT02598050

Intervention type: OTHER
Intervention: No Interventions as this is a observational study
Study: NCT03863782

Intervention type: OTHER
Intervention: No intervention
Description: No specific intervention. Collection of clinical data
Study: NCT00778219

Intervention type: DEVICE
Intervention: devices for tracheal intubation
Description: tracheal intubation by laryngoscope or lightwand
Study: NCT01373606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Study: NCT01686178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-smoking social marketing campaign
Description: We will utilize industry market research tools to define the target audience (segment of community with high smoking prevalence and high social influence) and directly counter tobacco industry lifestyle marketing strategies through local promotion of a smokefree brand and branded bar and club events.
Study: NCT02947061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 plus Docetaxel
Description: S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine plus Docetaxel
Description: Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
Study: NCT02566135

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal Intubation using I-gel and ventilating bougie
Description: Following general anaesthesia I-gel was inserted. After proper placement . ventilating bougie was inserted. Once it's placement is confirmed I-gel was removed keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie then it (v.bouggie) was removed . Proper placement of endotracheal tube was confirmed by bilateral equal chest excursion and air entry on auscultation, absence of gastric insuffflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for I-gel, ventilating bougie and endotracheal tube.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal Intubation using C-LMA and ventilating bougie
Description: Following general anaesthesia C-LMA was inserted. After proper placement of C-LMA, ventilating bougie was inserted. It's placement was confirmed and C-LMA was removed after deflation of cuff keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie. It's placement was confirmed by bilateral equal air entry and chest excursion, absence of gastric insufflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for C-LMA , ventilating bougie and endotracheal tube.
Study: NCT01533857

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: hot water
Description: Hot water and placebo capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black tea and phenolic acids
Description: Black tea extract and capsule with phenolic acids
Study: NCT02114931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABP 501
Description: Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501
Study: NCT00590356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StarClose®
Description: Closure device for femoral artery suture site occlusion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AngioSeal®
Description: Closure device for femoral artery suture site occlusion
Study: NCT00778219

Intervention type: DEVICE
Intervention: devices for tracheal intubation
Description: tracheal intubation by laryngoscope or lightwand

Intervention type: DEVICE
Intervention: devices for tracheal intubation
Description: tracheal intubation by laryngoscope or lightwand
Study: NCT02809313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment Gingivitis with Probiotic
Description: gingivitis treatment (scaling and coronary polish) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment Gingivitis conventional
Description: gingivitis treatment (scaling and coronary polish) and one sachet containing Placebo (talc powder) per day during 3 months
Study: NCT03657420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is a steroid which is believed to kill cancer cells
Study: NCT03754335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: Patient will be managed according to the current international recommendations in the Toulouse acute stroke center.~In the absence of clear recommendation in the literature headache will be treated according to our local predefined analgesic protocol: paracetamol 1g/6 h, and if the numerical scale ≥ 4 : continuous intravenous morphine starting at 1mg/h and increased per 0.5 mg/h every hour if numerical scale remains ≥ 4.~Lumbar puncture will be performed between day 3 and day 5 after subarachnoid hemorrhage onset by an independent scientist from our clinical investigator center. 30-mL CSF will be removed by LP.~Sham LP consisting in superficial skin puncture by a subcutaneous needle (27 gauge needle) during the usual procedure will be performed at the same time point.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar puncture
Description: Patient will be managed according to the current international recommendations in the Toulouse acute stroke center.~In the absence of clear recommendation in the literature headache will be treated according to our local predefined analgesic protocol: paracetamol 1g/6 h, and if the numerical scale ≥ 4 : continuous intravenous morphine starting at 1mg/h and increased per 0.5 mg/h every hour if numerical scale remains ≥ 4.~Lumbar puncture will be performed between day 3 and day 5 after subarachnoid hemorrhage onset by an independent scientist from our clinical investigator center. 30-mL CSF will be removed by LP.~Sham LP consisting in superficial skin puncture by a subcutaneous needle (27 gauge needle) during the usual procedure will be performed at the same time point.
Study: NCT03894189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxapram Hydrochloride
Description: the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxapram Hydrochloride
Description: the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
Study: NCT00746148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: 10 weekly sessions of 45 minutes each
Study: NCT01512004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propiverine Hydrochloride
Description: drug of oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolterodine Extended-release Tablet
Description: 4mg/tablet; oral; once per day
Study: NCT01890681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby NAP SACC

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Back to Sleep
Study: NCT02445170

Intervention type: PROCEDURE
Intervention: Amputation
Description: Transmetatarsal or below-knee amputation

Intervention type: PROCEDURE
Intervention: Amputation
Description: Transmetatarsal or below-knee amputation
Study: NCT02115191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-octylcyanoacrylate
Description: After sedation with midazolam (0.5 mg/kg orally) a Foley catheterization with a 10 Fr gauge siliconized catheter will be placed, with the balloon inflated with 1.5 ml water to prevent bladder spasm. After this we will apply the adhesive by using dissecting forceps to approximate the edges of the UCF, and then apply it several thin layers of OCA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical reintervention
Description: The reoperation will consist on mobilizing dartos flaps and closing the defect in layers with absorbable sutures. Urinary bladder drainage will be provided with a 10 Fr silicone Foley catheter, with the balloon inflated with 1.5 ml water to prevent bladder spasm.
Study: NCT03832933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: 16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Protein Diet
Description: 16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:21%:25%.
Study: NCT01527448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (seroquel)
Description: During the study period, subjects will be receiving a treatment with Quetiapine XR. The starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment of quetiapine will determine whether the study doctor will increase the dosage of the subject's quetiapine. If the study doctor increases the quetiapine during the study, the maximum dosage allowable during the study is 300mg.